GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Cyclically Adjusted Book per Share

KalVista Pharmaceuticals (STU:4XC1) Cyclically Adjusted Book per Share : €8.13 (As of Jan. 2025)


View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

KalVista Pharmaceuticals's adjusted book value per share for the three months ended in Jan. 2025 was €2.833. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €8.13 for the trailing ten years ended in Jan. 2025.

During the past 12 months, KalVista Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 48.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2025-05-29), KalVista Pharmaceuticals's current stock price is €10.00. KalVista Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2025 was €8.13. KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 1.23.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of KalVista Pharmaceuticals was 1.33. The lowest was 0.00. And the median was 0.00.


KalVista Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for KalVista Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Cyclically Adjusted Book per Share Chart

KalVista Pharmaceuticals Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 5.46

KalVista Pharmaceuticals Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.95 5.46 5.33 6.54 8.13

Competitive Comparison of KalVista Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

KalVista Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, KalVista Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jan. 2025 was:

Adj_Book= Book Value per Share /CPI of Jan. 2025 (Change)*Current CPI (Jan. 2025)
=2.833/134.0288*134.0288
=2.833

Current CPI (Jan. 2025) = 134.0288.

KalVista Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201503 -26.124 99.621 -35.147
201506 28.116 100.684 37.428
201509 25.887 100.392 34.561
201512 24.078 99.792 32.339
201603 20.562 100.470 27.430
201606 17.051 101.688 22.474
201609 16.067 101.861 21.141
201701 3.373 102.456 4.412
201704 3.009 103.167 3.909
201707 2.386 103.278 3.096
201710 2.453 104.070 3.159
201801 2.170 104.578 2.781
201804 2.057 105.708 2.608
201807 1.786 106.324 2.251
201810 5.402 106.695 6.786
201901 5.284 106.200 6.669
201904 4.983 107.818 6.194
201907 5.100 108.250 6.315
201910 4.957 108.577 6.119
202001 4.531 108.841 5.580
202004 4.318 108.173 5.350
202007 3.622 109.318 4.441
202010 3.083 109.861 3.761
202101 2.668 110.364 3.240
202104 8.804 112.673 10.473
202107 8.462 115.183 9.847
202110 8.022 116.696 9.214
202201 7.491 118.619 8.464
202204 6.981 121.978 7.671
202207 6.584 125.002 7.059
202210 5.933 125.734 6.324
202301 5.015 126.223 5.325
202304 4.298 127.992 4.501
202307 3.676 128.974 3.820
202310 3.149 129.810 3.251
202401 2.351 130.124 2.422
202404 4.528 132.289 4.588
202407 3.698 132.708 3.735
202410 2.843 133.182 2.861
202501 2.833 134.029 2.833

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


KalVista Pharmaceuticals  (STU:4XC1) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

KalVista Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=10.00/8.13
=1.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of KalVista Pharmaceuticals was 1.33. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


KalVista Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


KalVista Pharmaceuticals Business Description

Traded in Other Exchanges
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

KalVista Pharmaceuticals Headlines

No Headlines